Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061577 | 0.78 | EP300 (0.42) | GRIK1EP300CES1TSHRF7 | |
| SCHEMBL1119166 | 0.73 | F7 (0.59) | TSHRF7F3POLBALDH1A1 | |
| SCHEMBL1119164 | 0.73 | F7 (0.59) | TSHRF7F3POLBALDH1A1 | |
| SCHEMBL1119162 | 0.73 | F7 (0.59) | TSHRF7F3POLBALDH1A1 | |
| SCHEMBL1785114 | 0.73 | EP300 (0.45) | GRIK1EP300CES1TSHRF7 | |
| SCHEMBL309931 | 0.73 | EP300 (0.45) | GRIK1EP300CES1TSHRF7 | |
| SCHEMBL7115099 | 0.71 | EP300 (0.48) | GRIK1EP300CES1TSHRF7 | |
| SCHEMBL22631566 | 0.71 | EP300 (0.43) | GRIK1EP300CES1TSHRF7 | |
| SCHEMBL205160 | 0.71 | GRIK1 (0.56) | GRIK1EP300TSHRF7F3 | |
| SCHEMBL7560057 | 0.70 | GRIK1 (0.59) | GRIK1EP300TSHRF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309742-B2 | Use of the PigD protein for catalyzing 1,4-additions of 2-oxoalkanoates to α, β-unsaturated ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100305337-A1 | Use Of The PIGD Protein For Catalyzing 1,4-Additions Of 2-Oxoalkanoates To Alpha, Beta-Unsaturated Ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2142657-B1 | USE OF THE PIGD PROTEIN FOR CATALYZING 1,4-ADDITIONS OF 2-OXOALKANOATES TO ALPHA, BETA-UNSATURATED KETONES | UNIV ALBERT LUDWIGS FREIBURG (DE) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305337-A1 | Use Of The PIGD Protein For Catalyzing 1,4-Additions Of 2-Oxoalkanoates To Alpha, Beta-Unsaturated Ketones | PGD, PC, PDK4 | GRIK1 913/4885EP300 3736/4885CES1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.